Gesynta Pharma Reaches Key Recruitment Milestone in Phase 2 Endometriosis Study

Gesynta Pharma AB, a Swedish clinical-stage pharmaceutical company focused on chronic inflammatory diseases, has announced that its Phase 2 NOVA clinical trial has reached a major milestone. The company confirmed that 50% of the planned 190 patients have now been randomized into the study, putting recruitment ahead of schedule.

The NOVA trial is evaluating vipoglanstat, an investigational non-hormonal and non-opioid treatment for endometriosis. Top-line results from the study are expected in 2027.

Focus on a Disease That Affects Millions of Women

Endometriosis is a chronic inflammatory condition that affects more than 10% of women of reproductive age worldwide. The disease can cause severe pain, inflammation, and fertility-related complications, significantly impacting daily life and overall well-being.

Despite the large number of women affected by the condition, treatment options remain limited, creating a strong need for new therapies that can effectively manage symptoms without relying on hormones or opioids.

About the NOVA Phase 2 Trial

The NOVA study, which stands for Non-hormonal Option – a Vipoglanstat Assessment trial, is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study being conducted across multiple sites in Europe.

The trial is designed to evaluate the efficacy and safety of two different dose levels of vipoglanstat in women living with endometriosis.

Data generated from the study will also help shape the design of a future Phase 3 clinical development program.

Recruitment Progress Highlights Strong Interest

According to Gesynta Pharma, reaching the halfway point in patient enrollment ahead of schedule reflects strong engagement from both clinical investigators and study participants.

Eva Johnsson, Chief Medical Officer and Vice President of Clinical Development at Gesynta Pharma, described the milestone as an important achievement for the program.

She noted that the rapid enrollment progress demonstrates both the commitment of participating clinical sites and the significant interest among women seeking better treatment options for endometriosis. She also emphasized the urgent need for new therapies in this area and said the company is focused on completing recruitment and moving into the next stage of evaluation.

Company Sees Important Step Toward Phase 3 Development

Patric Stenberg, Chief Executive Officer of Gesynta Pharma, said the NOVA study represents an important advancement in a therapeutic area where relatively few clinical trials are currently underway.

According to Stenberg, the trial is laying the groundwork for a future Phase 3 development program and supports the company's goal of delivering a treatment that is effective, safe, and well tolerated.

He added that the significant unmet medical need in endometriosis continues to drive the company’s development efforts.

How Vipoglanstat Works

Vipoglanstat is an orally administered drug candidate designed to reduce pain and inflammation associated with endometriosis.

The treatment works by targeting microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme involved in producing prostaglandin E2 (PGE2), a key inflammatory mediator found in endometriotic lesions.

By blocking this pathway, vipoglanstat aims to reduce inflammation and pain without relying on hormonal mechanisms or opioid-based therapies.

Preclinical and Clinical Data Support Development

Gesynta Pharma reported that preclinical studies have shown encouraging results for vipoglanstat.

In an advanced endometriosis model, the drug candidate significantly reduced pain-related behaviors and decreased the burden of endometriotic lesions.

Previous clinical studies have also demonstrated favorable safety and tolerability profiles, along with positive pharmacodynamic effects in humans. These findings have supported the continued clinical development of vipoglanstat as a potential new treatment option for women living with endometriosis.

Next Steps for the NOVA Program

With patient recruitment now halfway complete, Gesynta Pharma will continue enrollment across participating European sites. The company plans to complete patient recruitment before moving forward with the next stages of analysis and evaluation.

The Phase 2 NOVA study remains a key part of the company’s strategy to advance vipoglanstat toward late-stage development and potentially provide a new non-hormonal, non-opioid treatment option for women affected by endometriosis.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!